| Literature DB >> 33096677 |
Christina Nielsen1,2, Volkert Siersma3, Emma Ghaziani1, Nina Beyer1, S Peter Magnusson1,2, Christian Couppé1,2.
Abstract
Parkinson's disease (PD) is a neurodegenerative disease and a multidisciplinary approach to rehabilitation has been suggested as the best clinical practice. However, very few studies have investigated the long-term effects of a multidisciplinary rehabilitation approach, particularly regarding whether this can slow the progression of PD. The purpose was to investigate the short- and long-term effect of a 2-week multidisciplinary rehabilitation regimen on the PD-related decline in health-related quality of life (HRQOL), mobility, and muscle function. Individuals with PD (IPD) participated in a 2-week inpatient multidisciplinary rehabilitation regimen that focused on improving HRQOL, mobility, and muscle function. Data from the primary outcome: HRQOL (Parkinson's Disease Questionnaire 39, PDQ-39), secondary outcomes: handgrip strength, Timed-up and Go (TUG), Hospital Anxiety and Depression Scale (HADS), and Falls Efficacy Scale-International (FES-I) were compared at pre-visitation, before and after the 2-week regimen, and again at 4 and 10 months follow-up. In total, 224 patients with PD were included. There were short-term improvements in all outcomes. PDQ-39 was maintained at the same level as pre-visitation after 10 months follow-up. A 2-week multidisciplinary rehabilitation regimen improved short-term mobility, muscle function, and HRQOL in individuals with Parkinson's disease. HRQOL was maintained after 10 months demonstrating long-term effects.Entities:
Keywords: Parkinson’s disease; health-related quality of life; multidisciplinary rehabilitation; physical function
Mesh:
Year: 2020 PMID: 33096677 PMCID: PMC7589165 DOI: 10.3390/ijerph17207668
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
In- and exclusion criteria.
| Inclusion | Exclusion |
|---|---|
| Diagnosed with PD according to UK Brain Bank Criteria | Psychiatric or geriatric patients |
| Disease phase 2–3 | Patients with day care |
| Age over 18 years | Medicine or drug addiction |
| Independent in everyday life | Patients who had attended the rehabilitation offer earlier |
| Hoehn and Yahr stage 1–3 | Other neurological diseases |
Disease phase 2: maintenance phase; symptoms are bilateral, minor disability managed effectively by a drug regimen. Disease phase 3: complex phase; more expressed symptoms that become difficult to manage and more complications arise, medications become less effective, additional non-pharmacological approaches are needed.
Presentation of topics during the 2-week multidisciplinary rehabilitation regimen.
| Multidisciplinary Staff | Topic | Purpose |
|---|---|---|
| Neurologist | Parkinson’s disease | Insight in PD, symptoms and prognosis. |
| Neuropsychologist | Stress management | Increase knowledge on stress management; give concrete tools to deal with stress and prevention. |
| Nurse | Nutrition | Introduction to nutritious diets. |
| Occupational therapist | Coping | Give insight in ways to change habits and behavior and to find own resources. |
| Occupational therapist | Assistive devices | Give insight in difference assistive devices. |
| Physiotherapist | Dancing | Introduction to different types of dancing; inspiration to movement and moving of joy. |
| Physiotherapist | Mindfulness | To reduce the degree of stress and tension, introduction to meditation and exercises. |
| Physiotherapist | Nordic walking | Introduction to a physical activity which is feasible in everyday life. |
| Physiotherapist | Aqua training | Introduction to exercises in water; focus on coordination, mobility and truncus. |
| Physiotherapist | Resistance training | Introduction to exercises that could be performed at the gym and at home. |
| Physiotherapist | Theory on training | Increase knowledge on different training activities, effect, intensity and importance of training. |
| Psychologist | Emotional reactions with PD | Increase the understanding of emotions and PD, special emphasis on stress, crisis and sorrow. |
| Psychologist | Theme day for relatives | To increase knowledge on PD, talk to other relatives and exchange experiences. |
| Sex therapist | Sexuality and cohabitation | Advice and guidance on sexuality when a partner is sick with PD, relatives could participate. |
| Speech therapist | Voice | Increase knowledge of voice, respiration, communication, posture and mimic. |
Figure 1Diagram of the study. First contact: Neurologist. Pre-visitation: Outcome measurements performed at one of the two centers. Intervention period: 2 weeks rehabilitation regimen, a multidisciplinary approach. PDQ-39: Parkinson’s DiseaseQuestionnaire-39, TUG: Timed-up & Go, FES-I: falls-efficacy scale international, HADS: Hospital Anxiety and Depression Scale.
Figure 2Flowchart of included participants. CST: Center of Health and Rehabilitation, Danish Association for Rheumatism Skaelskoer. VRC: Vejlefjord Rehabilitation Center N: number.
Participant characteristics.
| Variables | Total | CST | VRC |
|---|---|---|---|
| Number of participants ( | 214 | 108 | 106 |
| Age (Mean ± SD) | 66.2 ± 2.8 | 66.2 ± 8.8 | 66.1 ± 5.7 |
| Sex (m/f) | 96/118 | 47/59 | 49/59 |
| Years of disease (Mean ± SD) | 7.5 ± 4.2 | 7.5 ± 3.5 | 7.5 ± 7.1 |
| Hoehn and Yahr (Mean ± SD) | 2.1 ± 1.1 | 2.1 ± 0.7 | 2.2 ± 0.7 |
Number of participants; age, sex, years of disease and Hoehn and Yahr. SD: Standard deviation. Rehabilitation centers: CST: Center for Health and Rehabilitation, Danish Association for Rheumatism, Skaelskoer. VRC: Vejlefjord Rehabilitation Center, Vejlefjord.
Mean values for outcome measurements.
| PRE | START | END | 4 Months | 10 Months | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Number ( | Mean ± SD | Number ( | Mean ± SD | Number ( | Effect Size | Sign. | Mean ± SD | Number ( | Effect Size | Sign. | Mean ± SD | Number ( | Effect Size | Sign. | |
|
| ||||||||||||||||
| PDQ-39 (0–100) | 26.0 ± 12.0 | 139 | 24.3 ± 11.5 | 196 | 22.7 ± 11.2 | 196 | 0.3 | ** | 22.2 ± 12.0 | 197 | 0.3 | ** | 25.9 ± 14.0 | 178 | 0.0 | §§ |
|
| ||||||||||||||||
| Grip strength (Kg) | ||||||||||||||||
| - Most affected side | 30 ± 10.7 | 142 | 30 ± 10.8 | 183 | 32 ± 10.4 | 183 | 0.2 | *## | 33 ± 12.3 | 146 | 0.3 | **## | NA | |||
| - Less-affected side | 34 ± 11.1 | 142 | 34 ± 11.3 | 183 | 34 ± 10.5 | 183 | 0.0 | NS | 35 ± 12.4 | 146 | 0.1 | ## | NA | |||
| TUG (Seconds) | 8.4 ± 3.1 | 144 | 8.5 ± 2.8 | 205 | 7.3 ± 3.1 | 205 | 0.4 | **## | 7.1 ± 2.3 | 157 | 0.4 | **## | NA | |||
| HADS_Depression | 5.1 ± 3.4 | 138 | 5.0 ± 2.9 | 191 | 4.1 ± 3.1 | 191 | 0.3 | **## | 4.7 ± 3.7 | 153 | 0.2 | § | NA | |||
| HADS_Anxiety | 6.7 ± 4.3 | 138 | 6.6 ± 4.3 | 191 | 5.4 ± 3.9 | 191 | 0.3 | **## | 5.9 ± 3.8 | 153 | 0.2 | NS | NA | |||
| FES-I | 25.3 ± 8.3 | 123 | 25.7 ± 8,2 | 185 | 25.4 ± 8.1 | 185 | 0.0 | NS | 25.1± 7.5 | 172 | 0.0 | NS | NA | |||
Mean values for outcome measurements are presented. PRE: pre-visitation, START: start-rehabilitation regimen, END: end-rehabilitation regimen. Raw effect sizes are calculated for the change from pre-visitation, start-rehabilitation regimen to end-rehabilitation regimen, 4 months and 10 months, respectively. No significant difference was found from pre-visitation and start-rehabilitation, only for PDQ-39. Sign. = Significant difference. Significant from pre-visitation: * (p < 0.01), ** (p < 0.001), Significant from start-rehabilitation: ## (p < 0.001). Significant from end-rehabilitation: § (p < 0.01), §§ (p < 0.001). “Start-rehabilitation” refers to start of multidisciplinary rehabilitation, whereas “end-rehabilitation” refers to end of rehabilitation that is after 2 weeks. “4 months” and “10 months” refers to 4 months and 10 months, respectively after end-rehabilitation. NS: non-significant. NA: not available. PDQ-39: Parkinson’s Disease Questionnaire-39. TUG: Timed-Up and Go. HADS: Depression: Hospital Anxiety and Depression Scale. HADS_Depression refers to “depression” part of test. HADS_Anxiety refers to “anxiety” of test. FES-I: Falls Efficacy Scale-International.